Top Markets
Coin of the day
Cortexyme, Inc. Cortexyme, Inc.

Cortexyme, Inc.

CRTX
Rang in aandelen #25179
Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to... Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to pioneering new therapies for Alzheimer's and various other degenerative conditions. The company's primary investigational drug, atuzaginstat (also known as COR388), is an orally delivered, small molecule inhibitor engineered to cross the blood-brain barrier and target gingipain. This compound is currently in Phase II/III clinical trials, where it is being assessed for its potential use in individuals with mild to moderate Alzheimer's disease, as well as for tackling oral squamous cell carcinoma, periodontitis, and coronavirus infections. Established in 2012, Cortexyme, Inc. is headquartered in South San Francisco, California.
Aandeelprijs
$1.95
Laatst gesynchroniseerd: 2022-07-29
Marktkapitalisatie
$52.48M
Verandering (1 dag)
2.63%
Verandering (1 jaar)
0.00%
Land
US
Handel Cortexyme, Inc. (CRTX)

Categorie

Dividendrendementgeschiedenis voor Cortexyme, Inc. (CRTX)
Het dividendrendement (TTM) van Cortexyme, Inc. (aandelsymbool: CRTX) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Cortexyme, Inc. (CRTX) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH
0.00%
US